# iSpecimen Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/iSpecimen Inc.). ## Overview iSpecimen Inc. operates a biospecimen procurement marketplace that connects medical researchers with hospitals, laboratories, and other specimen supply sites. The company uses proprietary software to search, manage workflow, and administer the sourcing and delivery of human biospecimens and associated data across its network. ## Products & services • Biospecimen procurement marketplace • Search and matching software for specimens • Workflow and order management tools • Specimen data and compliance administration • Researcher and supplier network access - **Biospecimen procurement** (75%) — Sourcing and delivering human specimens from hospitals, laboratories, and other supply sites. - **Marketplace software and workflow** (15%) — Proprietary tools for search, order routing, and coordination between researchers and suppliers. - **Data and administrative services** (10%) — Compliance, user management, reporting, and specimen-related data handling. - Biospecimen procurement marketplace - Search and matching software for specimens - Workflow and order management tools - Specimen data and compliance administration - Researcher and supplier network access ## Customers iSpecimen sells primarily to medical research customers that need specific biospecimens and associated data for studies, trials, and discovery work. It also serves hospitals, laboratories, and other supply sites that participate as specimen sources within the marketplace network. The platform is designed to reduce the friction of finding, qualifying, and moving specimens between these two sides of the market. - **Medical research customers** (primary) — Buy biospecimens and associated data for research, assay development, and study execution. - **Hospitals and laboratories** (primary) — Provide specimens into the marketplace and participate because the platform helps monetize available samples. - **Life science and biopharma researchers** (secondary) — Use the marketplace to source hard-to-find specimens for translational and clinical research. - **Other supply sites** (secondary) — Contribute specimens and related data when they can meet specific collection and data requirements. - Medical research organizations needing specific biospecimens - Biopharma and life science researchers sourcing study materials - Hospitals and laboratories supplying specimens into the network - Research teams needing specimen-linked data and compliance support - Users who value faster matching versus building internal sourcing networks ## Geography The company is based in the United States and its disclosures emphasize a networked marketplace rather than a single manufacturing footprint. Its operations depend on the location of participating hospitals, laboratories, and research customers, so geography is driven by where specimens can be sourced and where research demand exists. The available excerpts do not provide a formal country revenue split. - Headquartered in the United States - Business depends on U.S.-based research and supply networks - Specimens are sourced from distributed hospitals and laboratories - Customer demand follows life science research activity by region - No country-level revenue split was disclosed in the excerpts ## Strategy iSpecimen’s strategy is to grow usage on both sides of its marketplace by retaining researchers and expanding supplier participation. The company also invests in search, workflow, data, and administration features to improve platform engagement and liquidity, which are central to matching supply with demand efficiently. Management also indicates interest in adjacent opportunities that can leverage the marketplace infrastructure. - **Increase marketplace liquidity** (short-term) — A deeper two-sided network improves specimen matching and makes the platform more useful to both buyers and suppliers. - **Enhance platform functionality** (medium-term) — Better search, workflow, and reporting tools can improve user engagement and operational efficiency. - **Extend into adjacent opportunities** (medium-term) — The marketplace infrastructure may support related services beyond core biospecimen procurement. - Grow researcher and supplier usage of the marketplace - Improve platform liquidity to increase match rates - Invest in search, workflow, data, and admin functions - Support biospecimen procurement with proprietary software - Explore adjacent opportunities using the marketplace ## Risks The business depends on continued participation from both specimen suppliers and research customers, so weak network liquidity can reduce match rates and revenue opportunities. It is also exposed to life science research spending cycles, specimen availability, compliance requirements, and the operational complexity of sourcing perishable or highly specified materials on a just-in-time basis. As a smaller public company, it also faces financing, dilution, and execution risk while it develops its platform. - **Marketplace liquidity risk** [high] — The platform only works well if researchers and suppliers are both active, so weak participation on either side can impair matching and revenue generation. - **Life science research demand cyclicality** [medium] — Customer demand depends on research budgets and project activity, which can fluctuate with broader funding conditions. - **Operational sourcing and fulfillment risk** [high] — The company must locate, qualify, and deliver specific specimens quickly, and failures can affect customer satisfaction and repeat business. - **Compliance and data handling risk** [medium] — The marketplace handles user, specimen, and compliance information, so process failures could create legal or reputational issues. - **Financing and dilution risk** [medium] — As a smaller company, access to capital can influence platform investment and operating flexibility. - Two-sided marketplace risk if researcher or supplier usage weakens - Life science research spending can slow demand for specimens - Specimen sourcing is operationally complex and highly specific - Compliance and user management are important to platform trust - Financing and dilution risk can affect execution and capital access ## Accounting Revenue recognition is likely tied to completed specimen procurement and delivery, so timing depends on when orders are fulfilled rather than when specimens are first identified. The company also relies on estimates and judgments in its critical accounting policies, and its just-in-time model reduces inventory risk but can make period-to-period comparisons sensitive to order timing and specimen mix. As a smaller issuer, financing instruments and stock-based or other equity-related transactions may also affect reported results and dilution analysis. - **Revenue recognition timing** — Specimen orders and delivery completion - **Management estimates and assumptions** — Assets, liabilities, revenues, and expenses - **Quarterly comparability** — Period-to-period operating results - **Financing-related accounting** — Capital structure and earnings per share - Revenue timing depends on specimen procurement and delivery completion - Order mix and specimen type can affect quarter-to-quarter comparability - Critical estimates and assumptions affect reported assets and expenses - Just-in-time model limits inventory accounting but increases timing sensitivity - Financing transactions may affect dilution and interest expense --- *Last updated: 2026-04-29T05:12:31.018789+00:00*